Clinical trial
A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination…
NCT00451295 · Tanabe Pharma Corporation, Industry · Terminated
Key facts
| NCT number | NCT00451295 |
|---|---|
| Title | A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia |
| Official title | A Phase III, Double-Blind, Multi-Centre, Randomised, Parallel Group Design, Placebo-Controlled, Flexible Dose Study of MCI-196 in Combination With a Ca-Based Phosphate Binder in CKD Stage V Subjects on Dialysis With Hyperphosphatemia. |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease, Dialysis, Hyperphosphatemia |
| Intervention type | Drug |
| Interventions | MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®), Placebo |
| Enrollment | 6 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Mar 23, 2007 |
| Last update posted | Nov 15, 2011 |
| Countries | Czechia, France, Germany, Italy, North Macedonia, Poland, Serbia, South Africa, Spain, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: